| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/26/2004 | EP1421218A2 Model of autoimmune disease and methods for identifying agents against autoimmune disease |
| 05/26/2004 | EP1421199A2 Compositions and methods for treating neurodegenerative diseases |
| 05/26/2004 | EP1421198A2 Cell-based high-throughput screening methods |
| 05/26/2004 | EP1421191A2 Therapeutic binding molecules |
| 05/26/2004 | EP1421174A2 Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof |
| 05/26/2004 | EP1421111A2 Proteins associated with cell growth differentiation, and death |
| 05/26/2004 | EP1421108A2 Antimicrobial and anti-inflammatory peptides |
| 05/26/2004 | EP1421086A1 2-(AMINOMETHYL)-TETRAHYDRO-9-OXA-1,3-DIAZA-CYCLOPENTA a]NAPHTHALENYL DERIVATIVES WITH ANTIPSYCHOTIC ACTIVITY |
| 05/26/2004 | EP1421084A1 Polycyclic guanine phosphodiesterase v inhibitors |
| 05/26/2004 | EP1421077A2 Novel pyrazole analogs acting on cannabinoid receptors |
| 05/26/2004 | EP1421075A1 Piperidine derivatives useful as ccr5 antagonists |
| 05/26/2004 | EP1421074A1 Novel compounds |
| 05/26/2004 | EP1421071A2 Substituted piperazine and diazepane derivaives as histamine h3 receptor modulators |
| 05/26/2004 | EP1421070A1 New piperidinyl derivates as modulators of chemokine receptor activity |
| 05/26/2004 | EP1421067A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 05/26/2004 | EP1421065A1 Hydrazinopeptoids and their uses for treating cancers |
| 05/26/2004 | EP1421062A1 Novel cyclohexyl sulphones |
| 05/26/2004 | EP1420815A2 Beta-amyloid-analogue - t-cell epitop vaccine |
| 05/26/2004 | EP1420800A1 Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at 4) receptor activity |
| 05/26/2004 | EP1420794A1 Prostaglandin analogs as chloride channel opener |
| 05/26/2004 | EP1420791A1 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma |
| 05/26/2004 | EP1420790A1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine |
| 05/26/2004 | EP1420788A1 Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders |
| 05/26/2004 | EP1420785A2 SUBSTITUTED INDENO 1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF |
| 05/26/2004 | EP1420783A1 Stable emulsion composition |
| 05/26/2004 | EP1420782A1 Use of nefiracetam for treating neurodegeneration |
| 05/26/2004 | EP1420781A2 Analgetic pyrroline derivatives |
| 05/26/2004 | EP1420773A1 Amidine derivatives for treating amyloidosis |
| 05/26/2004 | EP1420772A2 Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases |
| 05/26/2004 | EP1420768A2 Methods and compositions for regulating memory consolidation |
| 05/26/2004 | EP1420745A2 Use of r-nsaid compounds for anti-hiv treatment |
| 05/26/2004 | EP1313499A4 Method for treating the central nervous system by administration of igf structural analogs |
| 05/26/2004 | EP1305082B1 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 05/26/2004 | EP1296996B1 Purine derivatives |
| 05/26/2004 | EP1216245B1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 05/26/2004 | EP1206474B1 Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
| 05/26/2004 | EP1187605A4 Non-malignant disease treatment with ras antagonists |
| 05/26/2004 | EP1161226B1 Phosphocholine linked prodrug derivatives |
| 05/26/2004 | EP1119359B1 2-methyl-thieno-benzodiazepine formulation |
| 05/26/2004 | EP1027332B1 Novel lactam metalloprotease inhibitors |
| 05/26/2004 | EP1023291B1 Dipyridoimidazolderivatives useful in treating central nervous system disorders |
| 05/26/2004 | EP1015433B1 Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-oles, method for the production and use thereof as medicaments |
| 05/26/2004 | EP1005445B1 N-alkanoylphenylalanine derivatives |
| 05/26/2004 | EP0968194B1 Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists |
| 05/26/2004 | EP0778768B1 Formulations and methods for providing prolonged local anesthesia |
| 05/26/2004 | EP0676205B1 Cerebral metabolism activator containing glucose ester derivative |
| 05/26/2004 | CN1500097A Human monoclonal antibodies to FC Alpha receptor (CD89) |
| 05/26/2004 | CN1500095A Polymer conjugates of neublastin and methods of using ssame |
| 05/26/2004 | CN1500090A Beta-carboline derivatives and its pharmaceutical use against depression and anxiety |
| 05/26/2004 | CN1500089A Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain |
| 05/26/2004 | CN1500082A Cyano-5ubstituted dihydropyrimidine compounds and their use to treat diseases |
| 05/26/2004 | CN1500078A Aryl oxime-piperazines useful as CCR5 antagonists |
| 05/26/2004 | CN1499978A Manufacture of hemoglobin-based oxygen carrier |
| 05/26/2004 | CN1499972A Imidazolyl derivatives as corticotropin releasing factor inhibitors |
| 05/26/2004 | CN1499970A Use of GAL3 receptor antagonists for treatment of. depression and/or anxiety and compounds useful in such methods |
| 05/26/2004 | CN1499968A Method of treatment of dopamine-related dysfuction |
| 05/26/2004 | CN1499967A Kappa opiate agonists for treatment of bladder diseases |
| 05/26/2004 | CN1499927A Erythropoietin ameliorates chemotheapy-induced toxicity in vivo |
| 05/26/2004 | CN1498623A Glycyrrhizic acid and its derivative used as RANTES inducer |
| 05/26/2004 | CN1498622A Neurotoxicity inhibiting compsns. contg. ginsenoside Rg3 or ginsenoside Rh2 transferring glu |
| 05/26/2004 | CN1498621A Application of ginsenoside Re for preparing medicine for curing dysmnesia |
| 05/26/2004 | CN1151268C Method for producing neurotrophon-3(NT-3) by using methanol yeast (pichia pastoris) and its application |
| 05/26/2004 | CN1151267C Method for producing human brain-derived neurotrophic factor NDNF by using methanol yeast (pichia pastoris) and its application |
| 05/26/2004 | CN1151167C Purine derivatives |
| 05/26/2004 | CN1151152C New polycyclicazindole compound, its preparation method are medicine composition containing same |
| 05/26/2004 | CN1151147C Indole derivatives as 5-HT receptor antagonist |
| 05/26/2004 | CN1151130C Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkane alcohol |
| 05/26/2004 | CN1151129C 2-acryl-3-substituted indoacetamide derivative and its medical application |
| 05/26/2004 | CN1151122C Tramadol, Salts thereof and process for their preparation |
| 05/26/2004 | CN1150944C Application of alkaline fibroblast growth factor in preparing medicine to prevent and cure cerebral injury |
| 05/26/2004 | CN1150917C Medicine containing active components of rhodiola crenulata root and preparig process thereof |
| 05/26/2004 | CN1150908C Prodn. method of seahorse powder capsule |
| 05/26/2004 | CN1150906C Medicine for curing epilepsy |
| 05/26/2004 | CN1150901C Use of 1-ar (alk)yl-imidazoline-2-one for treating anxietyand stress conditions |
| 05/26/2004 | CN1150900C Pharmaceutical compositions for oral administration, comprising active substance and cyclodextrin |
| 05/26/2004 | CN1150897C Injectable composition of non-steroidal anti-inflammatory drugs |
| 05/25/2004 | US6740777 Mercaptoalkyl benzoic acid derivative are useful for inhibiting naaladase (acetylated alpha-linked acidic dipeptidase/n-/) enzyme activity |
| 05/25/2004 | US6740772 Pgd2 agonists; sleep inducing action; intracerebral transition; stability |
| 05/25/2004 | US6740760 Such as 1-((s)-3-mercapto-2-methyl-propionyl)-(r)-pyrrol-idine-2-carboxylic acid for treating diseases associated with amyloidosis (alzheimer's disease, diabetes, and familial amyloid polyneuropathy) |
| 05/25/2004 | US6740746 Nucleotide sequences coding polypeptide for use in the treatment and detection of of cancer, coronary or cerebrovascular, hypertensive, diabetic, arthritic and vision defects |
| 05/25/2004 | US6740677 Anxiety, convulsions |
| 05/25/2004 | US6740676 Treating diseases controlled by or responsive to retinoic acid |
| 05/25/2004 | US6740672 Administering alosetron, tropisetron, ondansetron, granisetron and/or bemesetron |
| 05/25/2004 | US6740669 Varying solvent and/or duration of recrystallization; rufinamide orange book listed patent |
| 05/25/2004 | US6740666 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 05/25/2004 | US6740659 Treatment of dyskinesia |
| 05/25/2004 | US6740657 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists |
| 05/25/2004 | US6740656 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 05/25/2004 | US6740655 3',5'-cyclic nucleotide phosphodiesterase 4-specific inhibitors reduce eosinophil influx to the lungs; side effect reduction; antiinflammatory agent; antiallergens; respiratory system disorders, especially asthma |
| 05/25/2004 | US6740644 Chemical compounds |
| 05/25/2004 | US6740641 Administering to a patient for treatment of the pain a glucoside or glucuronide derivative of hydromorphone, dihydromorphine, or dihydroisomorphine or a pharmaceutically acceptable salt |
| 05/25/2004 | US6740638 Amino acid sequence has 87-99 peptide residues |
| 05/25/2004 | US6740309 Delivery of compounds for the treatment of migraine through an inhalation route |
| 05/25/2004 | US6740308 Composition comprising condensation aerosol formed by volatilizing antihistamine under conditions effective to produce heated vapor and condensing to form condensation aerosol particles having less than 5% degradation products |
| 05/25/2004 | US6740307 Delivery of β-blockers through an inhalation route |
| 05/25/2004 | CA2029419C Nmda-blocking pharmaceutical compositions |
| 05/21/2004 | WO2004042402A2 Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1) |
| 05/21/2004 | WO2004042077A2 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b) |
| 05/21/2004 | WO2004042076A2 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4a (pde4a) |
| 05/21/2004 | WO2004042063A1 Pharmaceutical composition for preparing a medicine for treating and/or preventing a pathology related to an obsessive behaviour or obesity |